JP2021531297A5 - - Google Patents
Info
- Publication number
- JP2021531297A5 JP2021531297A5 JP2021503559A JP2021503559A JP2021531297A5 JP 2021531297 A5 JP2021531297 A5 JP 2021531297A5 JP 2021503559 A JP2021503559 A JP 2021503559A JP 2021503559 A JP2021503559 A JP 2021503559A JP 2021531297 A5 JP2021531297 A5 JP 2021531297A5
- Authority
- JP
- Japan
- Prior art keywords
- release system
- osmotic
- core
- weight
- disorders
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185135.3 | 2018-07-24 | ||
| EP18185135 | 2018-07-24 | ||
| PCT/EP2019/069564 WO2020020790A1 (de) | 2018-07-24 | 2019-07-19 | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531297A JP2021531297A (ja) | 2021-11-18 |
| JP2021531297A5 true JP2021531297A5 (https=) | 2022-07-26 |
| JPWO2020020790A5 JPWO2020020790A5 (https=) | 2022-07-26 |
Family
ID=63041848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503559A Pending JP2021531297A (ja) | 2018-07-24 | 2019-07-19 | 経口投与可能であり、修飾された放出を有する薬学的投薬形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210283046A1 (https=) |
| EP (1) | EP3826619A1 (https=) |
| JP (1) | JP2021531297A (https=) |
| CN (1) | CN112469398A (https=) |
| CA (1) | CA3107174A1 (https=) |
| WO (1) | WO2020020790A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| WO2023284724A1 (zh) * | 2021-07-12 | 2023-01-19 | 上海博志研新药物技术有限公司 | 沙库巴曲缬沙坦钠缓释组合物、其制备方法及应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| ES2039287T3 (es) | 1987-01-14 | 1993-09-16 | Ciba-Geigy Ag | Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles. |
| US4892739A (en) * | 1988-04-25 | 1990-01-09 | Ciba-Geigy Corporation | Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties |
| DE19747261A1 (de) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AR053986A1 (es) * | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| CN100563637C (zh) * | 2006-10-13 | 2009-12-02 | 北京红林制药有限公司 | 一种控释给药的药芯组合物和控释制剂及其制备方法 |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
| CA3039735A1 (en) * | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
-
2019
- 2019-07-19 JP JP2021503559A patent/JP2021531297A/ja active Pending
- 2019-07-19 CA CA3107174A patent/CA3107174A1/en active Pending
- 2019-07-19 WO PCT/EP2019/069564 patent/WO2020020790A1/de not_active Ceased
- 2019-07-19 EP EP19740581.4A patent/EP3826619A1/de not_active Withdrawn
- 2019-07-19 CN CN201980048634.5A patent/CN112469398A/zh active Pending
- 2019-07-19 US US17/262,491 patent/US20210283046A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102695130B1 (ko) | 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도 | |
| JP5658172B2 (ja) | アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法 | |
| JP6017604B2 (ja) | ニフェジピンまたはニソルジピンおよびアンジオテンシンｉｉアンタゴニストおよび／または利尿剤を含む医薬投与形 | |
| US9937157B2 (en) | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| US8747898B2 (en) | Controlled release oral dosage form | |
| US6589553B2 (en) | Controlled release oral dosage form | |
| CN102348455A (zh) | 药物剂型的活性包衣 | |
| JP2012107048A (ja) | 時限拍動性薬物送達システム | |
| JP2021531297A5 (https=) | ||
| CN102138912A (zh) | 硝苯地平渗透泵控释片及其制备工艺 | |
| JP2021532113A5 (https=) | ||
| CN102258492B (zh) | 溴新斯的明缓释片剂及其制备方法 | |
| KR20080104146A (ko) | 고형 의약 제제 | |
| JP2008501741A (ja) | 多層制御放出性メチルフェニデートペレット | |
| US20100008987A1 (en) | Modified Release Pharmaceutical Composition of Bupropion Hydrochloride | |
| US20030035840A1 (en) | Controlled release oral dosage form | |
| KR102545274B1 (ko) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 | |
| US20080118554A1 (en) | Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant | |
| KR102369607B1 (ko) | 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물 | |
| CN101836963B (zh) | 一种治疗高血压的药物应用制剂 | |
| JPWO2020020790A5 (https=) | ||
| CN114681422B (zh) | 一种硝苯地平控释片及其制备方法 | |
| US20150174078A1 (en) | Sustained Release Formulations of Lorazepam | |
| WO2021057881A1 (zh) | 一种奥司他韦制剂 | |
| KR100411195B1 (ko) | 케토롤락 트로메타민이 함유된 서방형 펠렛 |